Who are Nevanac's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Loqoa, Xibrom, Xapit, Valecoxib, Mobic, (+)-Ketoprofen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nepafenac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Nevanac — Competitive Intelligence Brief

Nevanac (NEPAFENAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug [EPC]. Area: Metabolic.

marketed Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 2 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Nevanac (NEPAFENAC) — Harrow Health. Nevanac works by inhibiting the enzyme prostaglandin G/H synthase 2, which is involved in producing prostaglandins that cause pain and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nevanac TARGET	NEPAFENAC	Harrow Health	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2005-01-01
Loqoa	ESFLURBIPROFEN	Taisho Pharmaceutical Co., Ltd.	marketed		Prostaglandin G/H synthase 2	2015-01-01
Xibrom	BROMFENAC	Bausch Health	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	2005-01-01
Xapit	PARECOXIB		marketed	parecoxib	Prostaglandin G/H synthase 2	2002-01-01
Valecoxib	VALDECOXIB		marketed	valdecoxib	Prostaglandin G/H synthase 2	2001-01-01
Mobic	MELOXICAM	Boehringer Ingelheim	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2000-01-01
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-05-26 — Mobic · 10709713 · Method of Use · US
2030-05-26 — Mobic · 9974746 · Formulation · US
2030-05-26 — Mobic · 11253478 · Formulation · US
2030-08-31 — Mobic · 8545879 · Formulation · US
2033-03-31 — Mobic · 9526734 · Formulation · US
2035-03-31 — Mobic · 9808468 · Method of Use · US
2035-03-31 — Mobic · 9649318 · Formulation · US
2039-03-08 — Mobic · 11458145 · Method of Use · US
2039-03-08 — Mobic · 10881663 · Method of Use · US
2040-07-19 — Mobic · 12059423 · Compound · US
2041-07-31 — Mobic · 12263176 · Formulation · US

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug [EPC] class)

· 8 drugs in this class
Pfizer · 2 drugs in this class
Assiut University · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Centro Hospitalar Lisboa Ocidental · 1 drug in this class
Dartmouth-Hitchcock Medical Center · 1 drug in this class
Dr. Vishwanath Karad MIT World Peace University · 1 drug in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Generic (originally Boots Group) · 1 drug in this class
Boehringer Ingelheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nevanac — Competitive Intelligence Brief. https://druglandscape.com/ci/nepafenac. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab